Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation

Background: Management of inflammatory bowel disease (IBD) is increasingly focused on mucosal remission. We assessed the prevalence of mucosal inflammation during clinical remission, the clinical consequences, and the impact on disease course. Methods: IBD patients from two referral centers who underwent a surveillance colonoscopy while clinically in remission between January 2001 and December 2003 were included. Follow‐up ended May 1, 2009. Clinical data were collected from patient charts. Statistical analysis was performed using independent t‐tests and nonparametric tests. Results: In total, 152 IBD patients were included (98 [65%] ulcerative colitis, 46 [30%] Crohn's disease; 85 [56%] males). Median follow‐up was 6.8 years (interquartile range [IQR] 6–8). Forty‐seven (31%) patients had no signs of inflammation during endoscopy (group A). Of the remaining 105 (68%) patients, 51 (49%) had both endoscopic and histological inflammation (group B), 51 (49%) histological inflammation only (group C), two (2%) endoscopic lesions only (group D). Two years later, 29% of all patients had endoscopic inflammation and another 27% had only microscopic inflammation. In 39% the inflammation had resolved spontaneously. Inflammation was more often found in group B+C (n = 62/102; 61%) than in group A (n = 17/47; 36%; P = 0.21). Inflammation was not associated with more frequent clinical relapses nor with stricture formation, nor with the need for surgery. Conclusions: A large proportion of IBD patients have mucosal inflammation without clinical symptoms. Although one‐third recover spontaneously, mucosal inflammation in patients who are clinically in remission is associated with more severe mucosal disease activity, but not with more complications or symptomatic flares during follow‐up. (Inflamm Bowel Dis 2012)

[1]  R. Steele,et al.  Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) , 2010, Gut.

[2]  P. Rutgeerts,et al.  Importance of mucosal healing in ulcerative colitis , 2010, Inflammatory bowel diseases.

[3]  P. Rutgeerts,et al.  The potential for disease modification in Crohn's disease , 2010, Nature Reviews Gastroenterology &Hepatology.

[4]  A. Schoepfer,et al.  Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI , 2010, The American Journal of Gastroenterology.

[5]  Laurent Beaugerie,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.

[6]  M. Picco Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease , 2010 .

[7]  B F Warren,et al.  European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. , 2008, Journal of Crohn's & colitis.

[8]  M. Samsom,et al.  What predicts mucosal inflammation in Crohn's disease patients? , 2007, Inflammatory bowel diseases.

[9]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[10]  M. Bala,et al.  Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease , 2006 .

[11]  M. Schwartz,et al.  Is Endoscopy Necessary for the Measurement of Disease Activity in Ulcerative Colitis? , 2005, The American Journal of Gastroenterology.

[12]  A. Zinsmeister,et al.  PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis , 2004, Gut.

[13]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[14]  Bernhard Nafe,et al.  Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. , 2003, Gastroenterology.

[15]  S. Woolf,et al.  Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. , 2003, Gastroenterology.

[16]  J. Mayberry,et al.  Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease , 2002, Gut.

[17]  M. Vatn,et al.  Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. , 1999 .

[18]  M. Vatn,et al.  Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time , 1999, American Journal of Gastroenterology.

[19]  C. Kleer,et al.  Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. , 1998, The American journal of surgical pathology.

[20]  P. Rutgeerts,et al.  Is Ileoscopy With Biopsy Worthwhile in Patients Presenting With Symptoms of Inflammatory Bowel Disease? , 1998, American Journal of Gastroenterology.

[21]  E. Schrumpf,et al.  Relationship of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis , 1991, Seminars in liver disease.

[22]  S. Riley,et al.  Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.

[23]  R. Willén,et al.  Histologic and colonoscopic assessment of disease extension in ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.